These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 8707264)

  • 1. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.
    Rumi M; Del Ninno E; Parravicini ML; Romeo R; Soffredini R; Donato MF; Wilber J; Russo A; Colombo M
    Hepatology; 1996 Dec; 24(6):1366-70. PubMed ID: 8938163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase chain reaction.
    Lau GK; Davis GL; Wu SP; Gish RG; Balart LA; Lau JY
    Hepatology; 1996 Jun; 23(6):1318-23. PubMed ID: 8675145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two years versus six months of interferon therapy for chronic hepatitis C.
    Farrell GC
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
    Manesis EK; Papaioannou C; Gioustozi A; Kafiri G; Koskinas J; Hadziyannis SJ
    Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
    Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
    Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon treatment for hepatitis C virus infection in patients on haemodialysis.
    Chan TM; Wu PC; Lau JY; Lok AS; Lai CL; Cheng IK
    Nephrol Dial Transplant; 1997 Jul; 12(7):1414-9. PubMed ID: 9249778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.